Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BIOX Stock Forecast 2026-2027
$1.19
Current Price
$79.98M
Market Cap
Buy 0
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to BIOX Price Targets
+68.1%
To High Target of $2.00
+68.1%
To Median Target of $2.00
+68.1%
To Low Target of $2.00
BIOX Price Momentum
-22.2%
1 Week Change
-24.2%
1 Month Change
-81.5%
1 Year Change
-9.2%
Year-to-Date Change
-84.0%
From 52W High of $7.44
+1.7%
From 52W Low of $1.17
📊 TOP ANALYST CALLS
Did BIOX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bioceres is one of their latest high-conviction picks.
Latest BIOX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, BIOX has a neutral consensus with a median price target of $2.00 (ranging from $2.00 to $2.00). The overall analyst rating is Buy (6.0/10). Currently trading at $1.19, the median forecast implies a 68.1% upside. This outlook is supported by 0 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Austin Moeller at Canaccord Genuity, projecting a 68.1% upside. Conversely, the most conservative target is provided by Austin Moeller at Canaccord Genuity, suggesting a 68.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BIOX Analyst Ratings
0
Buy
3
Hold
0
Sell
BIOX Price Target Range
Low
$2.00
Average
$2.00
High
$2.00
Current: $1.19
Latest BIOX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BIOX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 2, 2026 | Canaccord Genuity | Austin Moeller | Hold | Maintains | $2.00 |
| Nov 14, 2025 | Canaccord Genuity | Austin Moeller | Hold | Maintains | $2.25 |
| Sep 10, 2025 | Lake Street | Ben Klieve | Buy | Maintains | $5.00 |
| Sep 10, 2025 | Canaccord Genuity | Austin Moeller | Hold | Downgrade | $2.50 |
| Jul 15, 2025 | Oppenheimer | Kristen Owen | Outperform | Maintains | $6.00 |
| Apr 22, 2025 | Oppenheimer | Kristen Owen | Outperform | Maintains | $7.00 |
| Feb 13, 2025 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $6.50 |
| Feb 7, 2025 | Lake Street | Ben Klieve | Buy | Maintains | $8.00 |
| Feb 7, 2025 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $7.00 |
| Jan 28, 2025 | Oppenheimer | Kristen Owen | Outperform | Maintains | $12.00 |
| Nov 13, 2024 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $9.50 |
| Oct 21, 2024 | Oppenheimer | Kristen Owen | Outperform | Maintains | $13.00 |
| Oct 17, 2024 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $10.00 |
| Sep 11, 2024 | Roth MKM | Scott Fortune | Buy | Maintains | $13.00 |
| Sep 11, 2024 | Oppenheimer | Kristen Owen | Outperform | Maintains | $16.00 |
| Sep 11, 2024 | Canaccord Genuity | Austin Moeller | Buy | Maintains | $12.50 |
| Sep 11, 2024 | Lake Street | Ben Klieve | Buy | Maintains | $13.00 |
| Jul 19, 2024 | Canaccord Genuity | Austin Moeller | Buy | Assumes | $17.00 |
| Jul 2, 2024 | Roth MKM | Scott Fortune | Buy | Reinstates | $15.00 |
| Feb 9, 2024 | Roth MKM | Brian Wright | Buy | Maintains | $21.00 |
Bioceres Crop Solutions Corp. (BIOX) Competitors
The following stocks are similar to Bioceres based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bioceres Crop Solutions Corp. (BIOX) Financial Data
Bioceres Crop Solutions Corp. has a market capitalization of $79.98M with a P/E ratio of 227.0x. The company generates $318.16M in trailing twelve-month revenue with a -17.7% profit margin.
Revenue growth is -16.4% quarter-over-quarter, while maintaining an operating margin of +8.9% and return on equity of -18.9%.
Valuation Metrics
Market Cap
$79.98M
Enterprise Value
$351.49M
P/E Ratio
227.0x
PEG Ratio
16.2x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
-16.4%
Gross Margin
+46.0%
Operating Margin
+8.9%
Net Margin
-17.7%
EPS Growth
-16.4%
Financial Health
Cash/Price Ratio
+22.0%
Current Ratio
0.9x
Debt/Equity
89.6x
ROE
-18.9%
ROA
-0.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bioceres Crop Solutions Corp. (BIOX) Business Model
About Bioceres Crop Solutions Corp.
What They Do
Develops innovative crop productivity solutions.
Business Model
Bioceres Crop Solutions generates revenue by offering a range of products and services that enhance crop productivity, including seed technologies, crop nutrition, and protection products. The company's focus on sustainability and resilience allows it to cater to the needs of farmers seeking to optimize their agricultural practices amidst climate challenges.
Additional Information
Bioceres emphasizes biotechnological research and development, positioning itself as a key player in the agriculture and biotechnology sectors. The company actively engages in partnerships and collaborations to broaden its market presence and influence, highlighting its commitment to sustainable agriculture.
Company Information
Sector
Basic Materials
Industry
Agricultural Inputs
Employees
751
CEO
Dr. Federico Trucco Ph.D.
Country
Argentina
IPO Year
N/A
Bioceres Crop Solutions Corp. (BIOX) Latest News & Analysis
Latest News
Quick Summary
Bioceres' 1Q26 results show declining revenue but improved gross margins and reduced OpEx. The company faces significant financial risks, including over $100 million in debt and high dilution risk for equity holders.
Why It Matters
Bioceres' revenue decline and severe financial risks raise concerns about its viability, potential dilution, and asset sales, impacting shareholder value and market confidence.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Bioceres Crop Solutions Corp. (BIOX) will hold its Q1 2026 earnings call on November 13, 2025, at 8:30 AM EST, featuring CEO Federico Trucco and Head of Investor Relations Paula Savanti.
Why It Matters
Bioceres Crop Solutions' Q1 earnings call provides insights into financial performance and operational strategies, crucial for assessing growth potential and investment risk.
Source: Seeking Alpha
Market Sentiment:
Neutral
Bioceres Crop Solutions Reports Fiscal First Quarter 2026 Financial and Operational Results
2 months ago
Quick Summary
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) reported fiscal Q1 financial results for the period ending September 30, 2025, focusing on agricultural productivity and climate resilience.
Why It Matters
Bioceres' financial performance highlights its growth in sustainable agriculture, signaling potential for long-term investment returns amid increasing climate resilience focus.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Bioceres Crop (BIOX) reported a quarterly loss of $0.12 per share, exceeding the Zacks estimate of a $0.04 loss, and a decline from a $0.09 loss per share a year prior.
Why It Matters
Bioceres Crop's larger-than-expected quarterly loss signals potential operational issues, negatively impacting investor confidence and possibly leading to stock price declines.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) will host a conference call on November 13, 2025, at 8:30 a.m. ET to discuss its Q1 fiscal results for the period ending September 30, 2025.
Why It Matters
Bioceres' upcoming earnings call will provide insights into its financial performance and growth in climate-resilient agriculture, impacting investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Bioceres Crop Solutions and the Colorado Wheat Research Foundation have formed a collaboration to develop and commercialize HB4® wheat in the U.S., focusing on climate resilience and innovation.
Why It Matters
The collaboration between Bioceres and CWRF signals potential growth in the wheat market, enhancing climate resilience and innovation, which may attract investor interest and boost stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About BIOX Stock
What is Bioceres Crop Solutions Corp.'s (BIOX) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Bioceres Crop Solutions Corp. (BIOX) has a median price target of $2.00. The highest price target is $2.00 and the lowest is $2.00.
Is BIOX stock a good investment in 2026?
According to current analyst ratings, BIOX has 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.19. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BIOX stock?
Wall Street analysts predict BIOX stock could reach $2.00 in the next 12 months. This represents a 68.1% increase from the current price of $1.19. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bioceres Crop Solutions Corp.'s business model?
Bioceres Crop Solutions generates revenue by offering a range of products and services that enhance crop productivity, including seed technologies, crop nutrition, and protection products. The company's focus on sustainability and resilience allows it to cater to the needs of farmers seeking to optimize their agricultural practices amidst climate challenges.
What is the highest forecasted price for BIOX Bioceres Crop Solutions Corp.?
The highest price target for BIOX is $2.00 from Austin Moeller at Canaccord Genuity, which represents a 68.1% increase from the current price of $1.19.
What is the lowest forecasted price for BIOX Bioceres Crop Solutions Corp.?
The lowest price target for BIOX is $2.00 from Austin Moeller at Canaccord Genuity, which represents a 68.1% increase from the current price of $1.19.
What is the overall BIOX consensus from analysts for Bioceres Crop Solutions Corp.?
The overall analyst consensus for BIOX is neutral. Out of 7 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are BIOX stock price projections?
Stock price projections, including those for Bioceres Crop Solutions Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 2:15 AM UTC